Market Analysis: International conference on Gynecology and Obstetrics.

Adamu Ishaku

Department of Microbiology Faculty of Natural and Applied Sciences Nasarawa State University, Keffi. Nasarawa State, Nigeria, E-mail: akyalaisac@yahoo.com

Gynaecology or gynecology is the medical practice dealing with the health of the female reproductive system (vagina, uterus, and ovaries) and the breasts. Outside medicine, the term means “the science of women”. Its counterpart is andrology, which deals with medical issues specific to the male reproductive system. Almost all modern gynaecologists are also obstetricians. In many areas, the specialities of gynaecology and obstetrics overlap.

Examples of conditions dealt with by a gynaecologist are:

- Cancer and pre-cancerous diseases of the reproductive organs including ovaries, fallopian tubes, uterus, cervix, vagina, and vulva
- Incontinence of urine
- Amenorrhoea (absent menstrual periods)
- Dysmenorrhoea (painful menstrual periods)
- Infertility
- Menorrhagia (heavy menstrual periods); a common indication for hysterectomy
- Prolapse of pelvic organs
- Infections of the vagina (vaginitis), cervix and uterus (including fungal, bacterial, viral, and protozoal)
- UTI and Pelvic Inflammatory Disease
- Premenstrual Syndrome
- Other vaginal diseases

There is some crossover in these areas. For example, a woman with urinary incontinence may be referred to a urologist.

Obstetricians and Gynaecologists face a wide variety of challenges: Managing the care of patients of all ages from puberty through menopause and beyond; treating both acute and chronic health conditions; and of course, managing risk through the pregnancy and childbirth process. The United States has a higher ratio of maternal death than at least 40 other countries, even though it spends more money per capita for maternity care than any other. The lack of a comprehensive, confidential system of ascertainment of maternal death designed to record and analyze every maternal death continues to subject U.S. women to unnecessary risk of preventable mortality. Maternal deaths must be reviewed to make motherhood safer.

The global gynaecological devices market is marked by a high degree of fragmentation due to the presence of numerous large manufacturers, reports Transparency Market Research (TMR) in a new business intelligence study. This leaves ample scope for market consolidation in the near future. Top companies like Boston Scientific Corporation, Cooper Surgical, and Olympus Corporation hold distinction on account of their widespread product portfolio and geographical outreach. These companies are struggling to introduce non-invasive devices to serve a larger consumer base which will eventually help expanding their geographical outreach.

The increasing demand for medical help for women-centric health issues is bringing in immense scope for growth in the gynaecological device market. The small regional players play an important role and hold a significantly higher share in the gynaecological device market. The increasing entry barriers and stringent rules and regulations for approval of a product are limiting the entry of new companies. Insufficient funding from venture capitalists is also creating a challenging situation for the entrance of newer companies.

The global market for women’s health therapeutics will grow from nearly $33.0 billion in 2015 to nearly $40.6 billion by 2020, with a compound annual growth rate (CAGR) of 4.2% for the period of 2015-2020.

Obstetricians and Gynaecologists face a wide variety of challenges: Managing the care of patients of all ages from puberty through menopause and beyond; treating both acute and chronic health conditions; and of course,
managing risk through the pregnancy and childbirth process. The United States has a higher ratio of maternal deaths than at least 40 other countries, even though it spends more money per capita for maternity care than any other. The lack of a comprehensive, confidential system of ascertainment of maternal death designed to record and analyze every maternal death continues to subject U.S. women to unnecessary risk of preventable mortality. Maternal deaths must be reviewed to make motherhood safer.

The global gynaecological devices market is marked by a high degree of fragmentation due to the presence of numerous large manufacturers, reports Transparency Market Research (TMR) in a new business intelligence study. This leaves ample scope for market consolidation in the near future. Top companies like Boston Scientific Corporation, Cooper Surgical, and Olympus Corporation hold distinction on account of their widespread product portfolio and geographical outreach. These companies are struggling to introduce non-invasive devices to serve a larger consumer base which will eventually help expanding their geographical outreach.

The increasing demand for medical help for women-centric health issues is bringing in immense scope for growth in the gynaecological device market. The small regional players play an important role and hold a significantly higher share in the gynaecological device market. The increasing entry barriers and stringent rules and regulations for approval of a product are limiting the entry of new companies. Insufficient funding from venture capitalists is also creating a challenging situation for the entrance of newer companies.

The infertility treatment devices market is expected to reach USD 3,698.92 Million by 2020 from USD 1,822.32 Million in 2015, at a CAGR of 15.21%. Infertility treatment devices are used in assisted reproductive technologies (ART) like in vitro fertilization, intracytoplasmic sperm injection, and surrogacy for the treatment of infertility.

In 2010, global population accounted about 6.15bn of which 49.7% was women. The same trend is expected to be existing by 2025. By 2025, the world population is forecasted to be 8.19bn of which 49.5% will be women. This forecasted figure explains the growth potential of the Women’s Health market till 2025. It is generally observed that women live longer as compared to men and undergo rapid hormonal, physiological and emotional changes in their life time. This factor is now working as a catalyst for providing better education and healthcare services to women in all countries across the globe.

All major countries also increasing their healthcare budget time to time fuelling the growth of Women’s Health Market. Also, the growing awareness of birth control methods in both developing and developed countries are the major driving factor for the growth of the market. Again, contraception and other birth control methods are supported by the governments in developing nations can be additional growth factor of the market.

The biotechnology industry is marked by high competition and so is the NGS market for clinical as well as research applications. Prominent participants are actively involved in R&D to develop novel rapid, small, and less expensive platforms. Service providers are embracing the trend of increasing the amount of constructed sequence reads for each cycle run.

Samuel George
Program Coordinator
Reproductive Medicine & Women Healthcare
2020